Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Great and thanks
My basic understanding is that flu v works from the inside out and normal vaccines work from the outside in.
The core remains the same whereas the surface changes
Although don’t quote me!
Swap - potentially. Please see below:
'In a study, “Programming Multifaceted Pulmonary T Cell Immunity by Combination Adjuvants,” published in Cell Reports Medicine, researchers described a T-cell-based vaccine strategy that reportedly is effective against multiple strains of influenza virus. The experimental vaccine, administered through the nose, delivered long-lasting, multi-pronged protection in the lungs of mice by rallying T cells that eliminate viral invaders through an immune response....
....The findings also aid understanding of how to induce and maintain T-cell immunity in the respiratory tract, a knowledge gap that has constrained the development of immunization strategies. The researchers believe the same approach could apply to several other respiratory pathogens, including the novel coronavirus that causes COVID-19.'
https://www.genengnews.com/news/t-cell-based-vaccine-effective-against-multiple-influenza-virus-strains/
I wonder if you could use the expertise garnered developing a universal flu vaccine to develop a multi tear universal covid vaccine
Hmmm
CJ - Covid immunity duration is still unknown, however several papers have questioned the longevity of any vaccines that may be approved e.g.
COVID-19 spread in the UK: the end of the beginning?
https://www.thelancet.com/article/S0140-6736(20)31689-5/fulltext
It's a bit long winded but the relevant paragraph concludes that:
'Immunisation with a COVID-19 vaccine might have to be repeated annually if the duration of immunity is short, as suspected to be the case for other coronaviruses.'
Hope that helps.
The first time I heard of the vaccine offering only a year's immunity was C.F. 2 weeks ago on a webinar presentation.
The Gaurdian - Covid vaccine tracker
'Researchers around the world are racing to develop a vaccine against Covid-19, with more than 170 candidate vaccines now tracked by the World Health Organization (WHO).'
https://www.theguardian.com/world/ng-interactive/2020/sep/30/covid-vaccine-tracker-when-will-a-coronavirus-vaccine-be-ready
'The chair of the UK government’s vaccine task force has damped hopes of finding a “silver bullet” that provides lifetime immunity against Covid-19 despite a week of positive trial results for potential inoculations.
Kate Bingham told the Financial Times it was more likely scientists would develop either a vaccine that provides a year’s immunity or one that only mitigates the symptoms of the virus.'
https://www.ft.com/content/f63f9e25-a291-4871-9d4b-2fcf93c4969e
Bear in mind, that any new and updated vaccines, will also need testing (similar to the influenza yearly vaccines) - the potential recurring revenue for Open Orphan could be enormous.